Genetic Therapy: Clinical Trials

17 trials of Genetic Therapy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 3 recruiting, 2 active not recruiting, 2 withdrawn. 17 Phase 2, 9 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 217Completed 7, Recruiting 3, Active not recruiting 2, Withdrawn 2, Enrolling by invitation 1, Suspended 1, Terminated 1
Phase 19Completed 2, Recruiting 2, Active not recruiting 1, Enrolling by invitation 1, Suspended 1, Terminated 1, Withdrawn 1
Phase 31Withdrawn 1

Follow Genetic Therapy: new trials by email Literature Review of Genetic Therapy trials Research Report on Genetic Therapy

Trials (filtered) newest first · largest first

All 17 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease
gene therapy - GBA1 Parkinson Disease
Phase 1 / Phase 2WithdrawnCapsida Biotherapeutics, Inc.2025-08-182026-06-22
A Clinical Trial of CAP-002 Gene Therapy in Pediatric Patients With Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy
gene therapy - Developmental and Epileptic Encephalopathy
Phase 1 / Phase 2TerminatedCapsida Biotherapeutics, Inc.12025-07-032026-06-10
Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure
AB-1002 - Congestive Heart Failure
Phase 2Active not recruitingAskBio Inc1502023-10-202025-12-03
An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3
Gene therapy, Enzyme Replacement Agent - Gaucher Disease, Type 3
Phase 2 / Phase 3WithdrawnAVROBIO2023-10-012023-08-09
Gene Therapy for IGHMBP2-Related Diseases
Gene Therapy - SMARD1, CMT2S
Phase 1 / Phase 2Enrolling by invitationMegan Waldrop102021-11-042026-10-30
Phase I/II Clinical Trial Stem Cell Gene Therapy in RAG1-Deficient SCID
Gene therapy - Severe Combined Immunodeficiency Due to RAG1 Deficiency
Phase 1 / Phase 2SuspendedVideja B.V.102021-07-232026-07-16
PDE6A Gene Therapy for Retinitis Pigmentosa
subretinal injection of rAAV.hPDE6A - Retinitis Pigmentosa
Phase 1 / Phase 2Active not recruitingSTZ eyetrial92019-09-242024-04-18
Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery
HSV-Tk, Valacyclovir, Bicalutamide - High-risk Prostate Cancer, Prostate Cancer
Phase 2RecruitingThe Methodist Hospital Research Institute602018-08-022021-04-06
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
ADV/HSV-tk (gene therapy) - Glioblastoma, Anaplastic Astrocytoma
Phase 1 / Phase 2RecruitingThe Methodist Hospital Research Institute622018-02-282026-03-30
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
ADV/HSV-tk (gene therapy) - Glioblastoma Multiforme, Astrocytoma, Grade III
Phase 1 / Phase 2RecruitingDavid Baskin MD622017-12-112026-03-30
A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111
BIIB111 - Choroideremia
Phase 2CompletedBiogen662017-11-292024-02-23
A Phase I/II Clinical Trial for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC
gene therapy - Aromatic L-amino Acid Decarboxylase (AADC) Deficiency
Phase 1 / Phase 2CompletedNational Taiwan University Hospital102014-10-222023-02-10
Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy
Low Dose: 16 mg Engensis (VM202), High Dose: 32 mg Engensis (VM202), Control- Placebo (normal saline) - Painful Diabetic Neuropathies
Phase 2CompletedHelixmith Co., Ltd.1042012-08-012025-10-06
ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCID
Gene Therapy, Busulfan - Immunologic Deficiency Syndromes
Phase 2CompletedFondazione Telethon122002-10-022024-01-29
Liver Transplantation With ADV-TK Gene Therapy Improves Survival in Patients With Advanced Hepatocellular Carcinoma
ADV-TK (adenovirus-thymidine kinase enzyme) gene therapy - Hepatocellular Carcinoma, Liver Transplantation
Phase 2CompletedBeijing Chao Yang Hospital402000-09-012006-03-09
Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer
gene therapy, interleukin-2 gene, methotrexate - Head and Neck Cancer
Phase 2CompletedH. Lee Moffitt Cancer Center and Research Institute2000-06-012013-05-30
Gene Therapy for ADA-SCID
gene transduced PBL and/or gene transduced HSC - Severe Combined Immunodeficiency Syndrome
Phase 1 / Phase 2CompletedIRCCS San Raffaele81992-03-012008-01-24

Conditions studied

Astrocytoma (2)  ·  Glioblastoma (2)  ·  Aromatic amino acid decarboxylase deficiency (1)  ·  Carcinoma, Hepatocellular (1)  ·  Choroideremia (1)  ·  Diabetic Neuropathies (1)  ·  Gaucher Disease (1)  ·  Head and Neck Neoplasms (1)  ·  Heart Failure (1)  ·  Hypesthesia (1)  ·  Immunologic Deficiency Syndromes (1)  ·  Neuralgia (1)  ·  Paresthesia (1)  ·  Parkinson Disease (1)  ·  Prostatic Neoplasms (1)

Sponsors

Capsida Biotherapeutics, Inc. (2)  ·  The Methodist Hospital Research Institute (2)  ·  AVROBIO (1)  ·  AskBio Inc (1)  ·  Beijing Chao Yang Hospital (1)  ·  Biogen (1)  ·  David Baskin MD (1)  ·  Fondazione Telethon (1)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  Helixmith Co., Ltd. (1)  ·  IRCCS San Raffaele (1)  ·  Megan Waldrop (1)  ·  National Taiwan University Hospital (1)  ·  STZ eyetrial (1)  ·  Videja B.V. (1)

Countries

United States (10)  ·  Germany (3)  ·  Netherlands (2)  ·  Poland (2)  ·  Spain (2)  ·  Austria (1)  ·  Belgium (1)  ·  Bulgaria (1)  ·  Canada (1)  ·  China (1)  ·  France (1)  ·  Hungary (1)  ·  Israel (1)  ·  Italy (1)  ·  Romania (1)

Top investigators

Melanie Brandabur, MD (2)  ·  Arjan C Lankester, Prof.dr. (1)  ·  Bordignon Claudio, MD (1)  ·  David S Baskin, MD (1)  ·  David S. Baskin, MD (1)  ·  Ding Ma, M.D. (1)  ·  Dominik Fischer, Prof. (1)  ·  E. Brian Butler, MD (1)  ·  Fondazione Telethon (1)  ·  Jack Kessler, MD (1)  ·  Megan Waldrop, MD (1)  ·  Milena Veselinovic, MD, PhD (1)  ·  Ning Li, B.D (1)  ·  Thomas V. McCaffrey, MD, PhD (1)

Results publications

PMID 18218852, PMID 19179314, PMID 19633200, PMID 19652199, PMID 22184407, PMID 26000320, PMID 27129325, PMID 28319446, PMID 30169182, PMID 30194931, PMID 32322605, PMID 34763085, PMID 38355973, PMID 38970425, PMID 39878701

NIH funding

2017 (1), 2019 (1), 2023 (1)